Navigation Links
Moffitt Cancer Center researchers study use of dasatinib for patients with high-risk MDS
Date:3/20/2013

Researchers at Moffitt Cancer Center have completed a phase II clinical trial to determine the safety and efficacy of dasatinib for patients with higher-risk myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia, or acute myeloid leukemia resulting from MDS and have failed treatment with azanucleosides. The therapy may not be effective for all patients, but those with trisomy 8 chromosomal disorder have higher rates of stable disease and respond better to treatment with dasatinib, the study shows.

Results of this study appear in the March issue of Leukemia Research.

Myelodysplastic syndromes are disorders of the stem cell in bone marrow. The marrow does not produce enough normal blood cells for the body. As the number of quality blood-forming cells declines, blood production is impaired.

According to the researchers, stem cell transplantation is the only potentially curative option for MDS but also has risks of morbidity and mortality. A class of medication called azanucleosides is the only approved medication for patients with an advanced stage of this disease. The outcome after failure of azanucleosides is poor. Therefore, new therapies for MDS are needed, said the study authors.

Dasatinib, a multikinase inhibitor, has been approved by the Food and Drug Administration for patients with chronic myelogenous leukemia. The drug has promising potential because of its activity against a broad spectrum of tyrosine kinases, which are enzymes that function as an 'on' or 'off' switch for many cellular functions, such as increased activation of cell migration, proliferation, survival, invasion and angiogenesis (tumor blood vessel growth).

"This phase II trial was to assess whether dasatinib would be beneficial for patient with higher risk MDS whose previous treatments had failed," said study corresponding author Rami S. Komrokji, M.D., clinical director of Hematologic Malignancies and member of the Chemical Biology and Molecular Medicine Program at Moffitt. "We found that while dasatinib was well-tolerated with limited toxicities, it only had modest activity."

Among 18 patients treated, three patients responded, four had stable disease, and 10 experienced disease progression. They also noted that four of the five participants with trisomy 8, a disorder caused by having three copies of chromosome 8, had stable disease. An observation, they concluded, warrants further investigation.


'/>"/>

Contact: Kim Polacek
kim.polacek@moffitt.org
813-745-7408
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Related medicine news :

1. Cancer doesnt change young girls desire to have children, Moffitt Cancer Center study shows
2. Surgery and radiation improve survival for metastatic gastric cancer patients, Moffitt study shows
3. Moffitt researchers say silencing of retinoblastoma gene regulates differentiation of myeloid cells
4. Moffitt researchers find potential new therapeutic target for treating non-small cell lung cancer
5. Moffitt Cancer Center researchers develop automated breast density test linked to cancer risk
6. Tumor cells engineer acidity to drive cell invasion, Moffitt Cancer Center researchers say
7. New drug improves survival in multiple myeloma relapse, Moffitt Cancer Center researchers say
8. Moffitt study shows smoking cessation more successful for cancer patients who quit before surgery
9. Hispanics leery of health care providers, often avoid cancer screenings, Moffitt study shows
10. Moffitt researchers say effective immunotherapy for melanoma hinges on blocking suppressive factors
11. Moffitt Cancer Center researchers identify novel metabolic programs driving aggressive brain tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... The ... the Undersea and Hyperbaric Medical Society (UHMS), the leading authority in hyperbaric medicine. ... safety. Only a few hospitals and facilities have earned this distinction. This is ...
(Date:12/8/2016)... Islandia, NY (PRWEB) , ... December 08, 2016 ... ... company, is pleased to announce that “Natural Language Processing–Enabled and Conventional Data Capture ... published in JMIR Medical Informatics . , Results of the comparative usability ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... CURE Media ... centers and advocacy groups, has aligned with Upstage Lung Cancer in efforts to combat ... the announcement, Michael J. Hennessy, Jr said, “CURE Media Group is honored to team ...
(Date:12/8/2016)... ... 08, 2016 , ... Premier Fitness Camp (PFC) and The Chopra Center for ... and wellness program, at their world headquarters of Omni La Costa Resort & Spa ... to anyone seeking weight loss, personal development, a healthy lifestyle, or mental and physical ...
(Date:12/8/2016)... ... 2016 , ... Catalent Pharma Solutions, the leading global provider ... products, today announced that it had joined the Pharmaceutical Supply Chain Initiative (PSCI). ... unite pharmaceutical and healthcare companies that share a vision of better, social, environmental ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016 Global ... report on the global interventional radiology market analyzes ... The report comprises an elaborate executive summary, including ... various segments and sub-segments. The research is ... research formed the bulk of our research efforts ...
(Date:12/8/2016)... , Dec. 8, 2016  Diplomat Pharmacy, Inc. (NYSE: DPLO) ... a 2016 Top Workplaces National Standard. To ... ... Pharmacy (PRNewsFoto/Diplomat Pharmacy, Inc.) ... on an employee survey administered by WorkplaceDynamics, LLC, a research firm ...
(Date:12/8/2016)... and Markets has announced the addition of the "Endodontic Supplies - Global ... , ... markets for Endodontic Supplies in US$ Thousand. The report provides separate comprehensive analytics ... Europe , Asia-Pacific , Latin ... are provided for the period 2015 through 2022. Also, a six-year historic analysis ...
Breaking Medicine Technology: